8-K: Beneficient Closes $9.6 Million GP Primary Capital Transaction, Issues Convertible Preferred Stock

Beneficient closed a $9.6 million primary capital transaction, issuing Series B-6 Resettable Convertible Preferred Stock in exchange for a limited partner interest in an investment fund.

Summary

• Beneficient, through a subsidiary, completed a primary capital transaction involving a limited partner interest in an investment fund with a net asset value of $9.6 million.
• In exchange, the customer received 965,576 shares of Series B-6 Resettable Convertible Preferred Stock.
• This stock is convertible into Class A Common Stock at an initial conversion price of $0.3151 per share, subject to resets and a floor of $0.2363 per share.
• A maximum of 40,862,294 shares of Class A Common Stock may be issued upon conversion.
• The Series B-6 Preferred Stock has optional and mandatory conversion features, with mandatory conversion potentially occurring on the fifth anniversary of the original issue date, subject to certain conditions.
• The company filed a certificate of designation with the Secretary of State of Nevada, effective April 4, 2025, outlining the rights, preferences, privileges, and restrictions of the Series B-6 Preferred Stock.
• The company issued a press release on April 7, 2025, announcing the closing of the transaction.
• The transaction is expected to increase the collateral for the company's ExAlt loan portfolio by approximately $9.6 million.
• Upon closing of previously announced Public Stockholder Enhancement Transactions, the company believes this transaction will result in the addition of approximately $1.28 million (and an aggregate of approximately $10.46 million) of tangible book value attributable to the company's stockholders.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the successful closing of a $9.6 million capital transaction, which is expected to increase the collateral for the company's ExAlt loan portfolio and add to the tangible book value attributable to the company's stockholders. However, the potential dilution from the convertible preferred stock and the need for future stockholder approval temper the overall sentiment.

Positives

• The transaction provides Beneficient with $9.6 million in primary capital.
• The transaction is expected to increase the collateral for the company's ExAlt loan portfolio by approximately $9.6 million.
• The company believes this transaction will result in the addition of approximately $1.28 million (and an aggregate of approximately $10.46 million) of tangible book value attributable to the company's stockholders upon closing of previously announced Public Stockholder Enhancement Transactions.
• The transaction reinforces the company's ability to execute on its core liquidity and primary capital strategy.

Negatives

• The issuance of Series B-6 Preferred Stock dilutes existing shareholders.
• The conversion price of the Series B-6 Preferred Stock is subject to reset, which could further dilute existing shareholders.
• The company is reliant on future stockholder approval for the issuance of Class A Common Stock upon conversion of the Series B-6 Preferred Stock.

Risks

• The conversion of the Series B-6 Preferred Stock into Class A Common Stock is subject to certain limitations, including beneficial ownership limitations and exchange caps.
• The company's ability to meet expectations regarding the timing and completion of the transaction.
• The ultimate outcome of the transaction, including obtaining the requisite vote of securityholders.
• The company's reliance on the ExAlt loan portfolio and its ability to maintain and grow this portfolio.

Future Outlook

The company expects to build on this momentum and continue to pursue additional opportunities that align with its strategic vision and growth objectives.

Management Comments

• Successfully completing another GP primary capital transaction reinforces our ability to execute on our core liquidity and primary capital strategy by delivering innovative financing solutions for alternative asset holders and managers, said Beneficient management.
• We believe this financing reflects our ability to drive shareholder value while supporting impactful, vertically integrated investment strategies that enhance the value of the collateral backing our ExAlt loan portfolio.

Industry Context

This transaction reflects a growing trend of providing liquidity and primary capital solutions to holders of alternative assets, particularly in the venture capital space.

Comparison to Industry Standards

• It is difficult to compare this transaction directly to industry standards without more information on the specific terms and conditions of the Series B-6 Preferred Stock and the underlying investment fund.
• However, similar transactions in the private equity and venture capital space often involve the issuance of preferred stock or other convertible securities to raise capital.
• Companies like Apollo Global Management and Blackstone are active in providing capital solutions to alternative asset managers, but their transactions are typically much larger in scale.

Stakeholder Impact

• Shareholders may experience dilution upon conversion of the Series B-6 Preferred Stock.
• The transaction is expected to benefit the company by increasing its collateral and tangible book value.
• The transaction provides a primary capital solution to the general partner of the Pulse Pioneer Fund, LP.

Next Steps

• The company will file a preliminary proxy statement and a definitive proxy statement with the SEC to seek stockholder approval for the issuance of Class A Common Stock upon conversion of the Series B-6 Preferred Stock.
• The company will continue to pursue additional opportunities that align with its strategic vision and growth objectives.

Key Dates

Keywords

Series B-6 Preferred Stock, Primary Capital Transaction, Convertible Preferred Stock, Beneficient, ExAlt Loan Portfolio, Class A Common Stock, Alternative Assets, Financing